Biotech & Health Tech
Merck KGaA's writedown over Lonza deal; PharmaLogic buys Lantheus' CDMO business
Merck KGaA’s impairment hit from CDMO sale: The German conglomerate reported a €366 million ($405.8 million) impairment loss on its business sale to Lonza, according to its third-quarter earnings report Thursday. Last week, the company ...
Merck KGaA’s impairment hit from CDMO sale: The German conglomerate reported a €366 million ($405.8 million) impairment loss on its business sale to Lonza, according to its third-quarter earnings report Thursday. Last week, the company ...
This is a summary of the story. Read the full article at Endpoints News (Biopharma) ↗